Phase 1b study of Wnt inhibitor ipafricept (IPA) with nab-paclitaxel (Nab-P) and gemcitabine (G) in patients with previously untreated stage IV pancreatic cancer (mPDAC)

BACKGROUND: The recombinant fusion protein ipafricept (IPA) blocks Wnt signaling, and in combination with gemcitabine (G) and nab-paclitaxel (Nab-P) caused tumor regression in xenografts. This phase 1b study evaluated the combination of IPA with Nab-P+G in untreated metastatic PDAC (mPDAC) patients....

Fuld beskrivelse

Na minha lista:
Bibliografiske detaljer
Udgivet i:Clin Cancer Res
Main Authors: Dotan, Efrat, Cardin, Dana B., Lenz, Heinz-Josef, Messersmith, Wells, O’Neil, Bert, Cohen, Steven J., Denlinger, Crystal S., Shahda, Safi, Astsaturov, Igor, Kapoun, Ann M., Brachmann, Rainer K., Uttamsingh, Shailaja, Stagg, Robert J., Weekes, Colin
Format: Artigo
Sprog:Inglês
Udgivet: 2020
Fag:
Article
Online adgang:https://ncbi.nlm.nih.gov/pmc/articles/PMC7572624/
https://ncbi.nlm.nih.gov/pubmed/32694153
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/1078-0432.CCR-20-0489
Tags: Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!

Lignende værker